Finland: Faron Pharmaceuticals raises funds to complete Phase II of BEXMAB clinical trial

Faron Pharmaceuticals, a clinical-stage biopharmaceutical company, has issued a total of 30,709,056 new shares, corresponding to approximately 29.9% of the company’s shares and votes after the completion of the offering. The subscription […]